Executives

• A new compensation rule could cause difficulties for CEOs
• Johnson & Johnson Wades Into Death Penalty Debate For First Time
• Why Early Peeks at Drug Trials Are Giving Investors Whiplash

Lawyers, Regulatory and Compliance

• Sued for Retweeting – Yes, That Just Happened
• When do you use conventional versus digital inspection methods?
• A law professor’s big idea for combatting greedy drug company titans like Martin Shkreli
• FDA finalizes guidance on medical device interoperability
• Live from FDA/PDA: 3D Printing Applications, FDA releases statement

Promotional

• Lying Opioid pharma representative causes deaths
• A Cancer Conundrum: Too Many Drug Trials, Too Few Patients
• Novartis trial marks ResearchKit first in MS

Pricing, Reimbursement and Medical Affairs

• Express Scripts says new payment model needed for promising, but costly gene therapies
• Gamification of medical education: Choose Your Own Medventure
• An Easy Way to Cut Drug Costs

Clinical Trials

• Safety monitoring oversight adds value to your study
• Real World Evidence: FDA Commits to Advancing its Use

Manufacturing

• FDA to Fund Manufacturing Research Programs at NIPTE
• FDA teams with medical companies in Puerto Rico to tackle shortages
• Guidance: Post-Complete Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA

Pharmacy

• Pharmacists partner with doctors, not just pushing pills
• Former Monongahela pharmacist gets probation in drug-smuggling case
• U.S. Attorney Charges Pharmacy Tech for Tampering with Opioids

Medical Marijuana

• School Announces Bid to Test Medical Marijuana
• Medical Marijuana Company Requests Re-Vote From Town
• Pennsylvanians getting mixed messages about medical marijuana program

Privacy and Cybersecurity

• Smiths Medical could have a cybersecurity problem
• Why Cybersecurity Must be Part of Medical Device Architecture
• Why This Cybersecurity Expert Wants You Rethink What You Keep Secret

Futurism

• Left to Their Own Devices: The Promise and Dangers of IoT-Connected Medical Devices
• How Diseases Can Be Targeted Using Nanotechnology – And Why It’s Difficult
• Make way for the cyborg – why humans could be unrecognisable in the future

Food

• The ABCs of GMO Disclosure in the United States
• There’s More Evidence That The “Organic” Label Is Meaningless
• Dairy farmers address fear-based food labeling in campaign

Cosmetics

• More FDA regulations of cosmetics will not make them safer
• FDA Sets the Limits on Lead in Lipstick, Other Cosmetics
• The FDA Needs More Power to Regulate Toxic Chemicals in Cosmetics

Patient Advocacy

• Statement by FDA Commissioner Scott Gottlieb, M.D. on new steps by FDA to advance patient engagement in the agency’s regulatory work
• Startups Are Turning Customers into Lobbyists
• FDA discusses patient advocacy

Bioethics

• A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial
• A quiet revolution in organ transplant ethics
• An anarchist takes on the drug industry — by teaching patients to make their own meds